Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind Phase III trial comparing SCT630 versus adalimumab in moderate-to-severe plaque psoriasis
CTR20190933Phase 3Completed
- Sponsor
- Sinocelltech Group Limited
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SCT630 in plaque psoriasis, sponsored by Sinocelltech Group Limited. Started Jun 2019; status: completed.
02
Drugs
SCT630
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20190933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190933.